BioSpace News Archive

Phase IIa data showed AI Therapeutics’ ALS candidate increased expression of a target engagement biomarker and led to a 73% reduction in a toxic protein aggregate.

Phase III data for Pfizer’s respiratory syncytial virus vaccine candidate showed high levels of protection for older adults and infants.

At the World Vaccine Congress this week, Novavax presented data suggesting that its protein nanoparticle booster generated immune responses that could protect against severe infection.

Farallon Capital Management is waging a proxy battle with Exelixis over R&D spending. The hedge fund issued a letter to the company’s board of directors on Wednesday.

NLRB General Counsel Jennifer Abruzzo issued a memo to all field offices clarifying the board’s recent ruling in a case regarding severance agreements.

Innate Pharma SA announced the filing of its 2022 Universal Registration Document for the year ending December 31, 2022 with the French market authority “Autorité des Marchés Financiers” on April 6, 2023.

BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced that the Annual Report for 2022 has been published.

Sensorion a pioneering clinical-stage biotechnology company which specializes in gene therapies in the inner ear, will present new data supporting GJB2-GT program candidate selection to address hearing loss related to mutations in the GJB2 gene during the Company’s R&D Day taking place , Thursday, April 6, 2023.

Avacta Group plc announces the opening on 5 April 2023 of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug Application.The two sites, Memorial Sloan Kettering Cancer Center in New York and Fred Hutch Cancer Center in Seattle, are now open for patient enrolment to ALS-6000-101.

GC Cell, a Korean biotech company, announced on Apr. 6th that it has successfully attained the international certification for the anti-bribery management system, ISO 37001, from Korea Compliance Initiative, an international certification body.